Christopher Torrance

Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1988 and is headquartered in Winnersh, the United Kingdom.

Isogenica Ltd. provides research and development services in the fields of new peptide, antibody and other polypeptide drug candidates. It offers llamdA System, Xab System and 4D Fab System. The company was founded by Kevin Fitzgerald in 2000 and is headquartered in Little Chesterford, the United Kingdom.

Horizon Discovery Group Ltd. is a cell engineering company, which engages in the design and engineering of genetically-modified cells. The firm operates through the following business segments: Products, Services, and Leveraged Research & Development. The Products segment sells cell lines and other products. The Services segment offers cell line manufacturing services. The Leveraged Research & Development segment business unit is operated on a portfolio basis. It serves pharmaceutical, biotechnology, and diagnostic companies. The company was founded by Christopher John Torrance, Adam John Collier, and Alberto Bardelli in July 2005 and is headquartered in Cambridge, the United Kingdom.

PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom.

Exonate engages in the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. It develops SPHINXes, a pipeline of novel small molecule inhibitors. The company was founded by David Owen Bates, Lucy Donaldson, Steeven J. harper and Catherine Beech in 2013 and is headquartered in Nottingham, the United Kingdom.

O2h Ltd (O2h) is a venture capital firm. The firm is founded by Sunil and Prashant Shah. It is headquartered in United Kingdom.

Small Pharma Ltd. operates as a pharmaceutical company that develops a rapid-acting antidepressant to treat patients with depression. The company was founded by Peter Rands in 2015 and is headquartered in London, the United Kingdom.

NeoPhore Ltd. engages in discovery and development of small molecules inhibitors to treat cancer. The company is headquartered in Kings Cross, London, the United Kingdom.

Enhanc3D Genomics is a private functional genomics company based in Cambridge, UK. Enhanc3D Genomics is developing a technology to unlock the full potential of the three-dimensional organization of the human genome. The British company's focus is on the non-coding regions of the genome, aiming to identify disease-associated genetic interactions and revolutionize target and biomarker discovery. The company's unique approach has the potential to make precision medicine an everyday reality for patients. Enhanc3D Genomics Ltd. was founded by Mikhail Spivakov, Peter Fraser, and Stefan Schönfelder. The CEO is Hazel Jones.